Compare ADNT & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | ARDX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2016 | 2014 |
| Metric | ADNT | ARDX |
|---|---|---|
| Price | $21.90 | $5.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $25.41 | $15.14 |
| AVG Volume (30 Days) | 884.2K | ★ 3.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $17,439,000,000.00 | $2,607,000.00 |
| Revenue This Year | $2.71 | $37.75 |
| Revenue Next Year | $2.36 | $34.24 |
| P/E Ratio | $380.50 | ★ N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $16.14 | $3.54 |
| 52 Week High | $27.32 | $8.40 |
| Indicator | ADNT | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 36.36 |
| Support Level | $18.79 | $5.49 |
| Resistance Level | $23.22 | $6.23 |
| Average True Range (ATR) | 0.98 | 0.26 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 48.62 | 20.35 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.